PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Oculopharyngeal muscular dystrophy is caused by trinucleotide repeat expansions in thePABPN1gene. Here the authors use AAV-based gene therapy to knockdown the mutant gene and replace it with a wild-type allele, and show effectiveness in mice and in patient cells.
Guardado en:
Autores principales: | A. Malerba, P. Klein, H. Bachtarzi, S. A. Jarmin, G. Cordova, A. Ferry, V. Strings, M. Polay Espinoza, K. Mamchaoui, S. C. Blumen, J. Lacau St Guily, V. Mouly, M. Graham, G. Butler-Browne, D. A. Suhy, C. Trollet, G. Dickson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3641f54286a54c1ab1a1d2021d381ebf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An alanine expanded PABPN1 causes increased utilization of intronic polyadenylation sites
por: Tooba Abbassi-Daloii, et al.
Publicado: (2017) -
BETs inhibition attenuates oxidative stress and preserves muscle integrity in Duchenne muscular dystrophy
por: Marco Segatto, et al.
Publicado: (2020) -
Author Correction: Cytoskeletal disorganization underlies PABPN1-mediated myogenic disability
por: Cyriel Sebastiaan Olie, et al.
Publicado: (2021) -
Quantitative assessment of sitting time in ambulant adults with Muscular Dystrophy.
por: Matthew F Jacques, et al.
Publicado: (2021) -
Quantitative assessment of sitting time in ambulant adults with Muscular Dystrophy
por: Matthew F. Jacques, et al.
Publicado: (2021)